Nachrichten und Videos - DEXCOM INC.

Beginning Dec. 18, iLet users will have the option of using a Dexcom G7 CGM System. CONCORD, MA / ACCESSWIRE / December 7, 2023 / Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, announced today the nationwide launch of the iLet Bionic Pancreas automated insulin delivery system with the Dexcom G7 Continuous Glucose Monitoring (CGM) System planned for December 18, 2023 . With a firmware update, users will be able to update their iLet to...

Thinking about buying stock in Bitfarms, Mullen Automotive, SeaStar Medical Holding, NKGen Biotech, or DexCom? PR Newswire NEW YORK, Oct. 27, 2023 NEW YORK , Oct. 27, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BITF, MULN, ICU, NKGN, and DXCM. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. BITF:...

DexCom, Inc. (NASDAQ: DXCM), het wereldwijd toonaangevende bedrijf op het gebied van realtime continue glucosemonitoring voor mensen met diabetes, heeft vandaag nieuwe klinische onderzoeksresultaten bekendgemaakt die de voordelen van CGM-gebruik onderstrepen. Verder heeft het bedrijf tijdens de 59e jaarlijkse bijeenkomst van de European Association for the Study of Diabetes, gehouden van 2 tot 6 oktober 2023 in Hamburg, Duitsland, meer details gegeven over haar groeiende portfolio voor...

Dexcom, Inc (NASDAQ:DXCM), un chef de file mondial dans le domaine de la surveillance continue du glucose en temps réel (SCGtr), est fière d’annoncer que l’entreprise a obtenu la certification Great Place to Work ® au Canada pour 2023-2024. Décernée par le Great Place to Work Institute ® – l’autorité mondiale en matière de culture en milieu de travail –, cette certification repose directement sur une évaluation par les employés à propos de leur expérience en milieu de...

Dexcom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (rtCGM), is proud to announce that for the second consecutive year, it has been certified as a Great Place to Work ® in Canada for 2023-24. Awarded by Great Place to Work Institute ® , the global authority on workplace culture, this certification is based on direct feedback from employees about their workplace experience, and the sentiment of pride they feel in representing Dexcom. “Being recognized as a...

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2023. Second Quarter 2023 Financial Highlights: Revenue grew 25% versus the same quarter of the prior year to $871.3 million on a reported basis and 26% on an organic 1 basis. U.S. revenue growth of 21% and international revenue growth of 38% on a reported basis. International revenue growth was 40% on an organic 1 basis. GAAP operating income of $128.1 million or 14.7% of revenue, an...

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2023 financial results after market close on Thursday, July 27, 2023. Management will hold a conference call to review the company's second quarter 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future...

Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today that Health Canada has approved the next-generation Dexcom G7 Continuous Glucose Monitoring System for people with all types of diabetes, ages two years and older. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230704730937/en/ Dexcom G7 receives Health Canada approval. Compatible smart devices sold...

Dexcom, Inc. (NASDAQ : DXCM), un chef de file à l’échelle internationale dans le domaine de la surveillance continue du glucose (SCG) en temps réel pour les personnes atteintes de diabète, a annoncé aujourd’hui l’homologation par Santé Canada du système Dexcom G7 de surveillance continue du glucose pour les personnes atteintes de diabète qui sont âgées de deux ans et plus, sans égard au type de diabète. Ce communiqué de presse contient des éléments multimédias. Voir le...

Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people living with diabetes, announced today its strategy to bring Dexcom glucose sensing technology to millions more people around the globe and new Dexcom CGM research featured at the 83 rd Scientific Sessions of the American Diabetes Association being held June 23-26 in San Diego. During Dexcom’s Investor Day event held earlier today the company revealed plans to bring a new product to market...

DexCom, Inc. (NASDAQ:DXCM) today announced an update to its long-range financial targets at its 2023 Investor Day. Based on the company’s strong performance in the first two years of the target period, Dexcom is updating its year-end 2025 financial targets to the following levels: 2025 Revenue of approximately $4.6 - $5.1 billion (previously $4.0 - $4.5 billion) 2025 Non-GAAP Gross Profit Margin of 65%, consistent with prior guidance 2025 Non-GAAP Operating Profit Margin of 21% (previously...

DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today announced the Dexcom G6 Real-Time Continuous Glucose Monitoring System (rt-CGM) is the first and only CGM to connect to the Omnipod ® 5 AID System, helping users to protect against high and low glucose levels 1,2 . “For over a decade, Dexcom has been the sensor of choice for the development of AID systems. Dexcom has supported more than 50 studies around the world ranging...

As the UK marks the start of Diabetes Awareness Week, a new study reveals 84% of people surveyed agree having diabetes can negatively impact mental health. 1 The study, commissioned by DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, also found that nearly all those living with diabetes (91%) believe that technology enables them to continue building a balanced lifestyle whilst managing diabetes. 1 “As a pioneer and leader in...

DexCom, Inc. (NASDAQ:DXCM) today announced that it will host an Investor Day on June 23 rd from 2:30 PM until approximately 5:00 PM PST (5:30 PM – 8:00 PM EST). The event will include presentations from Dexcom management highlighting the company’s market opportunities, business strategy, innovation efforts, and long-term financial outlook. Links to a live webcast of the event will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for...

DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at William Blair's 43rd Annual Growth Stock Conference on Wednesday, June 7 th . The live presentation is scheduled to begin at approximately 1:40 PM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference....

According to the Center for Disease Control and Prevention, over 37 million people in the U.S. have diabetes. That's a little over ......

DexCom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase the accuracy, reliability and ease of use of its Dexcom G6 CGM System and will highlight the latest clinical evidence that continues to demonstrate the effectiveness of Dexcom CGM during the 66 th Annual Meeting of the Japan Diabetes Society held May 11-13, 2023 in Kagoshima, Japan. Dexcom G6 uses a small, wearable sensor and transmitter to continuously measure...

DexCom, Inc. (Nasdaq: DXCM) (“Dexcom”) announced today the pricing of its offering of $1.1 billion aggregate principal amount of 0.375% Convertible Senior Notes due 2028 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The aggregate principal amount of the offering was increased from the previously announced offering size of $1.0 billion....

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the publication of a study “Cost-Effectiveness of a Real-Time Continuous Glucose Monitoring System Versus Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on Insulin Therapy in the UK” in Diabetes Therapy 1 . This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230503005164/en/ In the...

DexCom, Inc. (Nasdaq: DXCM) (“Dexcom”) announced today that it intends to offer, subject to market conditions and other factors, $1.0 billion aggregate principal amount of Convertible Senior Notes due 2028 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Dexcom also intends to grant the initial purchasers of the notes an option to...